Search

Your search keyword '"Giovanni Spuria"' showing total 3 results
Start Over Author "Giovanni Spuria"
3 results on '"Giovanni Spuria"'

1. Impact of BNT162b2 Booster Dose on SARS-CoV-2 Anti-Trimeric Spike Antibody Dynamics in a Large Cohort of Italian Health Care Workers

Author

Laura V. Renna, Fabio Bertani, Alessandro Podio, Sara Boveri, Matteo Carrara, Arianna Pinton, Valentina Milani, Giovanni Spuria, Angelica F. Nizza, Sara Basilico, Carola Dubini, Ambra Cerri, Lorenzo Menicanti, Massimiliano M. Corsi-Romanelli, Alexis E. Malavazos, and Rosanna Cardani

Subjects
SARS-CoV-2, vaccine, immunity, BNT162b2, COVID-19, antibody, Medicine
Abstract

Accurate studies on the dynamics of Pfizer-Biontech BNT162b2-induced antibodies are crucial to better tailor booster dose administration depending on age, comorbidities, and previous natural infection with SARS-CoV-2. To date, little is known about the durability and kinetics of antibody titers months after receiving a booster dose. In this work, we studied the dynamic of anti-Trimeric Spike (anti-TrimericS) IgG titer in the healthcare worker population of a large academic hospital in Northern Italy, in those who had received two vaccine doses plus a booster dose. Blood samples were collected on the day of dose 1, dose 2, then 1 month, 3 months, and 6 months after dose 2, the day of the administration of the booster dose, then 1 month and 3 months after the booster dose. The vaccination immunogenicity was evaluated by dosing anti-TrimericS IgG titer, which was further studied in relation to SARS-CoV-2 infection status, age, and sex. Our results suggest that after the booster dose, the anti-TrimericS IgG production was higher in the subjects that were infected only after the completion of the vaccination cycle, compared to those that were infected both before and after the vaccination campaign. Moreover, the booster dose administration exerts a leveling effect, mitigating the differences in the immunogenicity dependent on sex and age.

Published
2023
Full Text
View/download PDF

2. Antibody responses to BNT162b2 mRNA vaccine: Infection‐naïve individuals with abdominal obesity warrant attention

Author

Teresa Cuppone, Lelio Morricone, Gianluca Iacobellis, Valentina Milani, Luca Carpinelli, Marta Sacchi, Matteo Carrara, Giovanni Spuria, Sara Basilico, Ilaria Prandoni, Federico Ambrogi, Federico Boniardi, Gloria Capitanio, Sara Boveri, Rosanna Cardani, Michele O. Carruba, Alexis Elias Malavazos, Lorenzo Menicanti, Francesco Secchi, Laura Valentina Renna, Enzo Nisoli, Roberta Rigolini, Carola Dubini, Elena Costa, Massimiliano Marco Corsi Romanelli, and Aurelia D'acquisto

Subjects
COVID-19 Vaccines, Waist, Endocrinology, Diabetes and Metabolism, Medicine (miscellaneous), Adipose tissue, Endocrinology, Immune system, Humans, Medicine, Attention, Obesity, BNT162 Vaccine, Abdominal obesity, Vaccines, Synthetic, Messenger RNA, Nutrition and Dietetics, biology, SARS-CoV-2, business.industry, Confounding, COVID-19, medicine.disease, Obesity, Abdominal, Antibody Formation, Immunology, biology.protein, mRNA Vaccines, Antibody, medicine.symptom, business
Abstract

OBJECTIVE The excess of visceral adipose tissue might hinder and delay immune response. How people with abdominal obesity (AO) will respond to mRNA vaccines against SARS-CoV-2 is yet to be established. We evaluated SARS-CoV-2 specific antibody responses after the first and second dose of the BNT162b2 mRNA vaccine comparing the response of individuals with AO to those without, discerning between individuals with or without prior infection. METHODS IgG neutralizing antibodies against the Trimeric-complex (IgG-TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose 1, at one and three months after dose 2. Nucleocapsid antibodies were assessed to detect prior SARS-CoV-2 infection. Waist circumference was measured to determine AO. RESULTS Between the first and third month after vaccine dose 2, the drop in IgG-TrimericS levels was more remarkable in individuals with AO compared to those without AO (2.44 fold [95%CI: 2.22-2.63] vs 1.82 fold [95%CI: 1.69-1.92], respectively, p

Published
2022

3. Antibody responses to BNT162b2 mRNA vaccine: infection-naïve individuals with abdominal obesity warrant attention

Author

Sara Boveri, Gloria Capitanio, Alexis Elias Malavazos, Matteo Carrara, Massimiliano Marco Corsi Romanelli, Marta Sacchi, Elena Costa, Maria Teresa Cuppone, Federico Ambrogi, Ilaria Prandoni, Laura Valentina Renna, Valentina Milani, Lorenzo Menicanti, Luca Carpinelli, Rosanna Cardani, Sara Basilico, Carola Dubini, Michele O. Carruba, Enzo Nisoli, Gianluca Iacobellis, Aurelia D'acquisto, Federico Boniardi, Giovanni Spuria, Francesco Secchi, and Lelio Morricone

Subjects
education.field_of_study, Waist, biology, business.industry, Confounding, Population, Physiology, Adipose tissue, Serology, Immune system, biology.protein, Medicine, medicine.symptom, Antibody, business, education, Abdominal obesity
Abstract

ObjectiveThe excess of visceral adipose tissue might hinder and delay the immune response. How people with abdominal obesity will respond to mRNA vaccines against SARS-CoV-2 is yet to be established. We evaluated SARS-CoV-2-specific antibody responses after the first and second dose of the BNT162b2 mRNA vaccine comparing the response of individuals affected by abdominal obesity (AO) to those without, discerning between individuals with or without prior infection.MethodsIgG neutralizing antibodies against the Trimeric complex (IgG-TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose-1, at one month and three months after dose-2. Nucleocapsid antibodies were assessed to detect prior SARS-CoV-2 infection. Waist circumference was measured to determine abdominal obesity.ResultsBetween the first and third month after vaccine dose-2, the drop in IgG-TrimericS levels was more remarkable in individuals with AO compared to those without AO (2.44 fold [95%CI: 2.22-2.63] vs 1.82 fold [95%CI: 1.69-1.92], respectively, pConclusionsOur findings highlight the need to extend the duration of serological monitoring of antibody levels in infection-naive individuals with abdominal obesity, a higher-risk population category in terms of possible weaker antibody response.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results